high dose tirzepatide study Lilly Decides to Advance for Obesity Tirzepatide (Zepbound) for weight loss

Noom, the leading digital healthcare company committed to chronic disease prevention and empowering people to live better longer, announced it will offer compounded GLP-1 injections paired with Nooms powerful GLP-1 companion program, providing a sustainable pathway off the medications

Overall, the GLP-1 group had a significantly better survival rate and a lower risk of AFib

These medications are commonly prescribed for type 2 diabetes and for weight management, and clinicians counsel patients up front about potential nausea and other GI effects

As you begin your treatment, you have 24/7 access to specialized support

Retatrutide's Phase 3 trials started in 2024, putting a 2027 to 2028 approval in line with that trajectory

Count on us as we guide you along your health path